Switzerland-based Actelion Pharmaceuticals has revealed results of the first randomised controlled trial of Opsumit (macitentan) in treating portopulmonary hypertension (PoPH), it was reported yesterday.
The results indicated that Opsumit significantly improved pulmonary vascular resistance compared with placebo, meeting the primary endpoint of the study. Presented as a late-breaking oral presentation at the European Respiratory Society meeting in France, the portopulmonary hypertension Treatment with macitentan, a randomised clinical trial that indicated the safety of macitentan in portopulmonary hypertension, was consistent with that observed in previous clinical trials.
The product is an orally active endothelin receptor antagonist that is presently approved in the US and Europe for the treatment of pulmonary arterial hypertension.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review